HNSPF.US Hansoh Pharmaceutical Group Company Limited

Healthcare Drug Manufacturers - Specialty & Generic USA Stocks
4.08 USD
Close of Nov 14, 2026
3.57 4.82
Market cap
USD 24.7B
P/E
25.5x
P/B
4.37x
ROE
15.7%
Dividend yield
1.52%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is HNSPF.US undervalued?

Graham number
Price4.08
Graham value1.83
Premium122.5%

HNSPF.US trades 122.5% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hansoh Pharmaceutical Group Company Limited fundamental analysis

No fundamental analysis for Hansoh Pharmaceutical Group Company Limited yet.

Hansoh Pharmaceutical Group Company Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pula…

Full company profile